Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Pharma Market Up 3.3% in FY2021, Opdivo Rises to No.1: IQVIA
May 26, 2022
- Vabysmo, Ondexxya, Ozempic 2 mg Pen Now Available in Japan
May 26, 2022
- Novavax Vaccine Officially Added to Japan’s Free COVID-19 Inoculation Program
May 26, 2022
- BMS CEO Sees Faster Drug Development as Industry Imperative after COVID Vaccine Feat
May 25, 2022
- US Business Made or Broke FY2021 Earnings of Big 3 Generic Makers; Nichi-Iko, Sawai Suffer Losses
May 24, 2022
- Healios Continues to Seek MultiStem Approval despite Trial Miss: CEO
May 24, 2022
- Tohoku Univ., Drug Makers, MICIN to Jointly Collect Lifestyle Data with Wearable
May 24, 2022
- OrphanPacific Grabs Japan Rights to Immedica Drug for Urea Cycle Disorder
May 24, 2022
- Shionogi President Teshirogi to Also Become Chairman from July
May 24, 2022
- First Wipe Drug for Axillary Hyperhidrosis Now Available in Japan
May 24, 2022
- Healios’ Sakigake Cell Therapy Misses Goal in Ischemic Stroke
May 23, 2022
- US Court Dismisses Astellas Claim over Lexiscan Patent
May 23, 2022
- Movicol High-Dose Version Launched for Constipation: EA Pharma
May 23, 2022
- Fostering Biopharma Startups Is Vital to New Drug Development in Japan: IQVIA
May 20, 2022
- Opdivo Expands Indication in Taiwan for RCC in Combo with Cabozantinib
May 20, 2022
- A Few More Years before Human Trials Can Start for Potential Diabetes Cure, Novo CSO Says
May 20, 2022
- AbbVie’s Japan Sales Sag 13% in 2021 as Off-Year Price Cuts, Synagis Return Weigh
May 19, 2022
- Sosei, Kallyope Partner in R&D of GPCR Targets for GI Drug Discovery
May 18, 2022
- Argenx CEO Sees Big Potential for Vyvgart with 100-Plus Diseases Driven by IgGs; Analysts Peg Peak Sales at US$5-10 Billion
May 18, 2022
- AstraZeneca Ranks Third in Japan Sales Ranking with 12.1% Growth, Good Start in Q1 Too
May 18, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…